Skip to Content
Interactive Textbook on Clinical Symptom Research Logo

Home Button

Anorexia Case Study Sections
Author Bio
Introduction
Commentator Bio
Currently selected section: Protocol Schema
Protocol Background
Protocol Goals
Patient Eligibility
Test Schedule
Stratification Factors
Registration/Randomization
Protocol Treatment
Dosage Modification
Ancillary Treatment
Toxicity Monitoring
Treatment Evaluation
Treatment/Follow-up
Ancillary Studies
Drug Information
Statistical Considerations
Pathology Considerations
Records/Data Collection Procedures
Budget
Appendices

 

Chapter 2A: Measuring Cancer Anorexia/Cachexia: A Case Study: Protocol Schema
 

Complete Text of Megace Morinol Study Protocol

Microphone image

Double-Blind Conditions. Cancer patients with weight loss and/or decreased caloric intake. Randomization leads to: A) Megace liquid (800 mg PO qd) plus Placebo capsule (PO bid), or B) Marinol capsule (2.5 mg PO bid) plus Placebo liquid (PO qd), or C) Megace liquid (800 mg PO qd) plus Marino capsule (2.5 mg PO bid) all lead to continue treatment as long as MD and patient feel it is beneficial. This leads to event monitoring.

Page 4 of 34